Literature DB >> 6282200

Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin.

C E Cherubin, M L Corrado, M F Sierra, M E Gombert, M Shulman.   

Abstract

The activities of cefotaxime, moxalactam, MK 0787 (N-formimidoyl thienamycin), ampicillin, oxacillin, vancomycin, and clindamycin were compared against gram-positive cocci. MK 0787 was the most active and moxalactam was the least active of these drugs, except against methicillin-resistant Staphylococcus aureus, where vancomycin was most active, and penicillin-resistant pneumococci, where cefotaxime was more active.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6282200      PMCID: PMC181744          DOI: 10.1128/AAC.20.4.553

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Use of autoclaved extracts of hemolytic streptococci for serological grouping.

Authors:  L A RANTZ; E RANDALL
Journal:  Stanford Med Bull       Date:  1955-05

2.  In vitro activity of thienamycin.

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.

Authors:  R Wise; T Rollason; M Logan; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

4.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

6.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

7.  Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa.

Authors:  M L Corrado; S H Landesman; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

  7 in total
  15 in total

1.  A clinical view of vancomycin in 1990.

Authors:  W T Siebert
Journal:  Tex Heart Inst J       Date:  1990

2.  Failure of routine susceptibility tests to detect imipenem resistance among strains of methicillin-resistant Staphylococcus aureus.

Authors:  J M Boyce; E Papa; R Dickenson; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 3.  Chemotherapy for bacterial infections of the central nervous system.

Authors:  N M Ampel; E L Labadie
Journal:  West J Med       Date:  1987-09

4.  Overproduction of a 37-kilodalton cytoplasmic protein homologous to NAD+-linked D-lactate dehydrogenase associated with vancomycin resistance in Staphylococcus aureus.

Authors:  W M Milewski; S Boyle-Vavra; B Moreira; C C Ebert; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Cefotaxime in the treatment of meningitis.

Authors:  C E Cherubin; J LeFrock
Journal:  Infection       Date:  1985       Impact factor: 3.553

6.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 7.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

8.  Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections.

Authors:  W Fan; R del Busto; M Love; N Markowitz; C Cendrowski; J Cardenas; E Quinn; L Saravolatz
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

9.  Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections.

Authors:  D J Winston; M A McGrattan; R W Busuttil
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

Review 10.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.